Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBITDA (2021 - 2025)

Krystal Biotech (KRYS) has disclosed EBITDA for 5 consecutive years, with $51.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 17.5% to $51.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $206.2 million through Dec 2025, up 133.39% year-over-year, with the annual reading at $206.2 million for FY2025, 133.39% up from the prior year.
  • EBITDA hit $51.4 million in Q4 2025 for Krystal Biotech, down from $79.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $80.6 million in Q3 2023 to a low of -$51.0 million in Q1 2022.
  • Historically, EBITDA has averaged $4.8 million across 5 years, with a median of -$7.8 million in 2021.
  • Biggest five-year swings in EBITDA: crashed 222.47% in 2022 and later surged 726360.0% in 2025.
  • Year by year, EBITDA stood at -$22.0 million in 2021, then tumbled by 42.59% to -$31.3 million in 2022, then skyrocketed by 131.02% to $9.7 million in 2023, then soared by 350.75% to $43.8 million in 2024, then rose by 17.5% to $51.4 million in 2025.
  • Business Quant data shows EBITDA for KRYS at $51.4 million in Q4 2025, $79.3 million in Q3 2025, and $39.1 million in Q2 2025.